GROWTH HORMONE AXIS / FAQ
Questions From the Literature
Direct, citation-anchored answers to the questions readers most often bring to the CJC-1295 + ipamorelin research stack and its individual components.
What is CJC-1295 / Ipamorelin good for?
In research terms, the CJC-1295 + ipamorelin combination is studied for its ability to co-stimulate two independent pituitary receptor pathways — the GHRH receptor and the ghrelin receptor (GHS-R1a) — producing a growth hormone pulse larger than either component alone [5][7]. The GHRH-analogue class that includes CJC-1295 has been studied in humans for body-composition outcomes: a 2026 meta-analysis of five RCTs of the related analogue tesamorelin found significant reductions in visceral adipose tissue and hepatic fat, increased lean body mass, and elevated IGF-1 [1]. However, the fixed CJC-1295 + ipamorelin combination itself has never been evaluated in a controlled clinical trial for any specific indication [2]. This site does not advise on use.
What are the bad side effects of CJC-1295 and Ipamorelin?
The documented cautions from the literature include: GH-related effects (fluid retention, carpal-tunnel-type tingling, joint discomfort, and blood-glucose perturbation) arising from the class-level mechanism [2]; injection-site reactions; and the class-level cardiovascular signal from a 28-day study of a related ghrelin-receptor agonist that showed dose-dependent myocardial changes in rats [13] — a signal that has never been replicated or ruled out for ipamorelin specifically. Anecdotally (not clinical evidence), research-use community accounts also describe facial flushing, water retention and puffiness, grogginess, and lightheadedness after injection. Long-term safety is uncharacterized for both compounds; neither has been studied in long-term human trials [2].
How long do CJC-1295 and Ipamorelin take to work?
The pharmacokinetics are very different between the two. CJC-1295 with DAC begins raising GH within hours of a subcutaneous dose and sustains elevated GH for 6 or more days and elevated IGF-1 for 9–11 days or more; with repeated doses, IGF-1 remained above baseline for up to 28 days [3]. Ipamorelin (from IV studies) produces a single discrete GH pulse peaking around 40 minutes post-dose, with a terminal half-life of approximately 2 hours [15]. Whether any downstream physiological effects from repeated dosing emerge quickly or accumulate over weeks is not established in controlled human studies of the combination. This site does not advise on timing or protocols.
How many mg of CJC-1295 and Ipamorelin should I take?
This site does not provide human dosing recommendations for any research peptide. The doses in the published literature were used under controlled research conditions in specific species and are reported here only as scientific descriptors — for example, 30–60 micrograms per kilogram for CJC-1295 in healthy adults [3], or 0.03 mg/kg intravenously for ipamorelin in the bowel-resection trial [14]. The fixed combination has never been studied in a controlled clinical trial for any indication, so there is no evidence-based human dose for the combination. Readers with clinical questions should consult a licensed clinician in their own jurisdiction.
What is CJC-1295?
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH), built on the first 29 residues of natural hGRF with four stabilizing amino-acid substitutions. Its DAC (Drug Affinity Complex) variant adds a maleimidopropionyl linker that covalently binds the Cys34 thiol of serum albumin in vivo, extending its half-life from minutes to several days [4]. A 2025 Nature Reviews Endocrinology review covers the current pharmacology of the GHRH-analogue class that includes CJC-1295, sermorelin, and tesamorelin [8]. CJC-1295 is not an approved drug — it was identified in a seized unlabeled pharmaceutical preparation by LC-MS/MS [9] and is sold only as a research chemical.
What does CJC-1295 do?
CJC-1295 binds the GHRH receptor on anterior-pituitary somatotrophs and activates the Gs/cAMP/PKA cascade that drives GH synthesis and pulsatile release, which then stimulates hepatic IGF-1 production. In healthy adults, a single subcutaneous dose raised mean plasma GH two- to ten-fold for six or more days and IGF-1 one-and-a-half to three-fold for 9–11 days; after multiple doses, IGF-1 remained above baseline for up to 28 days [3]. Notably, GH pulsatility was preserved during continuous CJC-1295 stimulation — normal pulse frequency and amplitude continued even as the baseline was elevated [11]. In a serum proteomic study, CJC-1295 produced detectable shifts in apolipoprotein A1, transthyretin, and other proteins correlating with IGF-1 [10].
Is CJC-1295 safe?
CJC-1295 was generally well tolerated in the published healthy-adult pharmacodynamic studies [3][11], but "well tolerated in short-term PK studies" is not the same as established long-term safety. A review of growth hormone secretagogues identifies increased blood glucose from decreased insulin sensitivity as the chief metabolic concern for the class [2], and CJC-1295's multi-day GH and IGF-1 elevation means this signal is sustained rather than transient. FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity, peptide-impurity, and cardiac-effect concerns [9]. There are no large-scale or long-term human safety trials of CJC-1295. This site does not advise on individual safety determinations — that is a question for a licensed clinician.
How much CJC-1295 should I take?
This site does not provide human dosing recommendations. Published doses — 30 or 60 micrograms per kilogram subcutaneously in the healthy-adult pharmacodynamic study [3] — are scientific descriptors, not recommendations. There are no evidence-based human dosing guidelines for CJC-1295 for any indication, no approved therapeutic use, and no controlled trial demonstrating efficacy or safety at any specific dose in a clinical population. Community dosing protocols circulating online are not derived from controlled human trials [2]. For any clinical consideration, consult a licensed clinician.
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that selectively activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs to trigger a pulse of growth hormone release. It is the GHS-R1a-agonist component of the CJC-1295 + ipamorelin research combination, and it functions through a mechanism — Gq/calcium signaling — that is mechanistically distinct from and complementary to the GHRH-receptor/cAMP pathway [5][6]. It is not an approved drug anywhere. Its only published Phase 2 RCT enrolled 114 bowel-resection patients and missed its primary endpoint [14]. It is prohibited in sport under WADA Section S2.
What does ipamorelin do for you?
In research models, ipamorelin triggers a discrete GH pulse at the ghrelin receptor without meaningfully raising ACTH, cortisol, or prolactin — even at doses more than 200 times its GH threshold [6]. In human IV pharmacokinetic studies, it produced a single GH pulse peaking around 40 minutes post-dose with a terminal half-life of approximately 2 hours [15]. In rats, repeated dosing increased longitudinal bone growth rate dose-dependently without changing total IGF-1 or bone-turnover markers [16]. The Phase 2 bowel-resection trial in humans did not demonstrate a statistically significant reduction in time to first tolerated meal [14]. Research-use community accounts describe sleep improvement and recovery benefits, but these are anecdotal, unverified, and not clinical findings.
What is ipamorelin peptide?
Ipamorelin is classified as a growth hormone secretagogue (GHS) or growth-hormone-releasing peptide (GHRP) — specifically the first selective GH secretagogue, meaning it releases GH without the non-selective hormonal side effects (ACTH/cortisol elevation) seen with earlier GHRPs like GHRP-6 [6]. It is also described as a ghrelin receptor agonist because it acts on GHS-R1a, the same receptor activated by the natural hunger hormone ghrelin. Its structure (Aib-His-D-2-Nal-D-Phe-Lys-NH2) carries D-configured and unnatural residues that protect it from the peptidases that would degrade simpler peptides rapidly. It is sold as a research chemical; pharmacokinetic data come from IV studies in human volunteers [15].
What are the risks of ipamorelin?
The cited risks from the literature: GH-axis stimulation raises theoretical concerns about GH-mediated effects on insulin sensitivity and IGF-1-driven cell proliferation [2]. A 28-day preclinical study of a structurally distinct GHS-R1a agonist found dose-dependent myocardial degeneration and necrosis in rats — a class-level cardiovascular signal that has not been replicated or ruled out for ipamorelin specifically in any equivalent long-duration animal study [13]. Ipamorelin additionally has a GH-independent insulinotropic and adipogenic effect via the ghrelin receptor [2]. Long-term human safety data do not exist: the only controlled human trial was a 7-day perioperative IV study [14], and research-grade purity from unregulated suppliers is unverified. These are not hypothetical concerns but documented gaps in the evidence record.